Clinical trial
Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni
NCT02280044 is registered in ClinicalTrials.gov with Johns Hopkins Bloomberg School of Public Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- October 31, 2014
- Completion date
- August 9, 2016
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.